美国孕妇普遍丙型肝炎病毒筛查的成本效果分析
该研究采用丙肝自然史马尔可夫模型,从医疗付费方视角比较普遍筛查与背景风险筛查的成本效果。
要点
- 普遍产前丙肝筛查在所有治疗资格情景下均具成本效果(平均ICER<$3000/QALY)。
- 筛查在0.07%的低患病率下仍具成本效果。
核心结论
- 美国孕妇普遍丙肝筛查具成本效果,应全国推荐。
主要发现
- 普遍产前筛查在所有治疗资格情景下均具成本效果(平均ICER<$3000/QALY)。
- 筛查在患病率0.07%(美国最低估计,夏威夷)时仍具成本效果。
关键数值与推荐
- 平均ICER<$3000/QALY(所有治疗资格情景)。
- 患病率0.07%时筛查仍具成本效果。
临床怎么用
- 支持对全美孕妇实施普遍丙肝筛查,而非仅风险筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus' (HCV) chronic prevalence among pregnant women in the United States doubled nationally from 2009-2014 (~0.7%), yet many cases remain undiagnosed. Screening pregnant women is not recommended by the Society of Maternal-Fetal Medicine or the Centers for Disease Control and Prevention, despite new American Association For the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines recommending screening for this group. We assessed the cost-effectiveness of HCV screening for pregnant women in the United States. METHODS: An HCV natural history Markov model was used to evaluate the cost-effectiveness of universal HCV screening of pregnant women, followed by treatment after pregnancy, compared to background risk-based screening from a health-care payer perspective. We assumed a HCV chronic prevalence of 0.73% among pregnant women, based on national data. We assumed no Medicaid reimbursement restrictions by fibrosis stage at baseline, but explored differing restrictions in sensitivity analyses. We assessed costs (in US dollars) and health outcomes (in quality-adjusted life-years [QALYs]) over a lifetime horizon, using new HCV drug costs of $25 000/treatment. We assessed mean incremental cost-effectiveness ratios (ICERs) under a willingness-to-pay threshold of $50 000/QALY gained. We additionally evaluated the potential population impact. RESULTS: Universal antenatal screening was cost-effective in all treatment eligibility scenarios (mean ICER <$3000/QALY gained). Screening remained cost-effective at a prevalence of 0.07%, which is the lowest estimated prevalence in the United States (in Hawaii). Screening the ~5.04 million pregnant women in 2018 could result in the detection and treatment of 33 000 women, based on current fibrosis restrictions. CONCLUSIONS: Universal screening for HCV among pregnant women in the United States is cost-effective and should be recommended nationally.
引用
- Chaillon A, Rand EB, Reau N, et al. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019. PMID: 30689769. doi:10.1093/cid/ciz063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。